Filing Flows › BeOne Medicines (ONC) › Q3 2026 › vs Q2 2026
BeOne Medicines (ONC) Q3 2026 vs Q2 2026 (quarter over quarter)
BeOne Medicines's revenue rose $185M (+11%) from $1.7B in Q2 2026 to $1.9B in Q3 2026. Gross margin 88.5% against 89.8% (-1.2 pts).
BeOne Medicines, Q3 2026: revenue $1.9B (+34% year over year), operating margin 22.2%, net earnings $385M, operating cash flow $509M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 88.5% | 89.8% | -1.2 pts |
| Operating margin | 22.2% | 19.1% | +3.1 pts |
| Net margin | 20.4% | 13.9% | +6.5 pts |
| Free cash flow margin | 25.1% | 25.5% | -0.5 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.9B | $1.7B | $185M | +11% |
| Gross profit | $1.7B | $1.5B | $142M | +9% |
| Cost of revenue | $217M | $175M | $42.4M | +24% |
| Operating profit | $419M | $325M | $93.6M | +29% |
| Operating expenses | $1.3B | $1.2B | $48.8M | +4% |
| Pre-tax earnings | $410M | $312M | $97.9M | +31% |
| Other expense, net | $8.3M | $12.6M | −$4.3M | -34% |
| Research & development | $661M | $612M | $48.5M | +8% |
| SG&A | $593M | $593M | $246K | 0% |
| Net earnings | $385M | $237M | $148M | +62% |
| Income tax | $25.7M | $75.5M | −$49.8M | -66% |
| Depreciation & amortization | $60.9M | $40.5M | $20.4M | +50% |
| Share-based compensation | $132M | $137M | −$4.9M | -4% |
| Working capital & other | $69.4M | −$47.9M | $117M | — |
| Operating cash flow | $509M | $463M | $45.9M | +10% |
| Free cash flow (OCF − capex) | $474M | $435M | $38.2M | +9% |
| Capital expenditures | $35.2M | $27.5M | $7.7M | +28% |
Questions
How much did BeOne Medicines's revenue grow quarter over quarter in Q3 2026?
BeOne Medicines's revenue rose $185M (+11%) from $1.7B in Q2 2026 to $1.9B in Q3 2026. Gross margin 88.5% against 89.8% (-1.2 pts).